CDC Yellow Book 2018: Health Information for International Travel
CDC Yellow Book 2018: Health Information for International Travel

Author: Centers for Disease Control and Prevention CDC

Publisher: Oxford University Press

Published: 2017-04-17

Total Pages: 705

ISBN-13: 0190628634

DOWNLOAD EBOOK

THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.

Hepatitis and Liver Cancer
Hepatitis and Liver Cancer

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2010-04-23

Total Pages: 252

ISBN-13: 0309153689

DOWNLOAD EBOOK

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

CDC Yellow Book 2020
CDC Yellow Book 2020

Author: Centers for Disease Control and Prevention (CDC)

Publisher:

Published: 2019

Total Pages: 721

ISBN-13: 0190065974

DOWNLOAD EBOOK

The definitive reference for travel medicine, updated for 2020 "A beloved travel must-have for the intrepid wanderer." -Publishers Weekly "A truly excellent and comprehensive resource." -Journal of Hospital Infection The CDC Yellow Book offers everything travelers and healthcare providers need to know for safe and healthy travel abroad. This 2020 edition includes: � Country-specific risk guidelines for yellow fever and malaria, including expert recommendations and 26 detailed, country-level maps � Detailed maps showing distribution of travel-related illnesses, including dengue, Japanese encephalitis, meningococcal meningitis, and schistosomiasis � Guidelines for self-treating common travel conditions, including altitude illness, jet lag, motion sickness, and travelers' diarrhea � Expert guidance on food and drink precautions to avoid illness, plus water-disinfection techniques for travel to remote destinations � Specialized guidelines for non-leisure travelers, study abroad, work-related travel, and travel to mass gatherings � Advice on medical tourism, complementary and integrative health approaches, and counterfeit drugs � Updated guidance for pre-travel consultations � Advice for obtaining healthcare abroad, including guidance on different types of travel insurance � Health insights around 15 popular tourist destinations and itineraries � Recommendations for traveling with infants and children � Advising travelers with specific needs, including those with chronic medical conditions or weakened immune systems, health care workers, humanitarian aid workers, long-term travelers and expatriates, and last-minute travelers � Considerations for newly arrived adoptees, immigrants, and refugees Long the most trusted book of its kind, the CDC Yellow Book is an essential resource in an ever-changing field -- and an ever-changing world.

Review of the Fialuridine (FIAU) Clinical Trials
Review of the Fialuridine (FIAU) Clinical Trials

Author: Institute of Medicine

Publisher: National Academies Press

Published: 1995-03-14

Total Pages: 279

ISBN-13: 0309176611

DOWNLOAD EBOOK

In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.

Eliminating the Public Health Problem of Hepatitis B and C in the United States
Eliminating the Public Health Problem of Hepatitis B and C in the United States

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2016-06-01

Total Pages: 187

ISBN-13: 0309438020

DOWNLOAD EBOOK

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Liver Pathophysiology
Liver Pathophysiology

Author: Pablo Muriel

Publisher: Academic Press

Published: 2017-03-02

Total Pages: 917

ISBN-13: 0128043210

DOWNLOAD EBOOK

Liver Pathophysiology: Therapies and Antioxidants is a complete volume on morphology, physiology, biochemistry, molecular biology and treatment of liver diseases. It uses an integral approach towards the role of free radicals in the pathogenesis of hepatic injury, and how their deleterious effects may be abrogated by the use of antioxidants. Written by the most prominent authors in the field, this book will be of use to basic and clinical scientists and clinicians working in the biological sciences, especially those dedicated to the study and treatment of liver pathologies. Presents the most recent advances in hepatology, with a special focus on the role of oxidative stress in liver injury. Provides in vivo and in vitro models to study human liver pathology. Explains the beneficial effects of antioxidants on liver diseases. Contains the most recent and modern treatments of hepatic pathologies, including, but not limited to, stem cells repopulation, gene therapy and liver transplantation.

Saliva Protection and Transmissible Diseases
Saliva Protection and Transmissible Diseases

Author: Crispian Scully

Publisher: Academic Press

Published: 2017-07-19

Total Pages: 124

ISBN-13: 0128136820

DOWNLOAD EBOOK

Saliva Protection and Transmissible Diseases provides a review of saliva protection, raising debate on micro-organisms potentially transmissible in saliva, and also considering the evidence on diseases that may be transmitted by kissing. Saliva is a complex body fluid essential to health, especially mastication, swallowing and speech, and hyposalivation can lead to dysfunction and even infection. More serious pathogens, such as herpes viruses and papillomaviruses can be conveyed by kissing, as can potentially lethal micro-organisms present in some saliva, such as meningococci, fungal organisms and Ebola viruses. Stipulates the defensive roles of saliva, an important topic not previously reviewed in-depth in literature Provides awareness that saliva also transmits infectious agents that can produce serious or even lethal diseases Gives understanding that kissing may be an at-risk practice

Hepatitis B Virus in Human Diseases
Hepatitis B Virus in Human Diseases

Author: Yun-Fan Liaw

Publisher: Humana

Published: 2015-11-23

Total Pages: 0

ISBN-13: 9783319223292

DOWNLOAD EBOOK

This text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for students, clinicians, and researchers with an interest in hepatitis B. The book reviews new data about basic and translational science including the viral life cycle, the immunopathogenesis of virus induced chronic hepatitis, the mechanism of virus induced liver cancer, and their potential applications for the clinical management of patients. The clinical aspects of this chronic viral infection are reviewed in detail with important chapters on the global epidemiology, the natural history of the disease, co-infections with its satellite virus HDV or HIV, and management of special patient populations. A major emphasis is made on the management of antiviral therapy and the recent international guidelines for the treatment of hepatitis B. Finally, the book reviews the current state of the art regarding immunoprophylaxis to prevent the spread of the virus and its major clinical consequences. The new advances and perspectives in the development of improved antiviral treatments are also discussed. Hepatitis B Virus in Human Diseases will serve as a very useful resource for students, physicians and researchers dealing with, and interested in, this challenging chronic viral infection. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and include the most up to date scientific and clinical information.

Liver Disease in Children
Liver Disease in Children

Author: Frederick J. Suchy

Publisher: Cambridge University Press

Published: 2007-05-07

Total Pages: 995

ISBN-13: 1139464035

DOWNLOAD EBOOK

Completely revised new edition of the premier reference on pediatric liver disease. Liver Disease in Children, 3rd Edition provides authoritative coverage of every aspect of liver disease affecting infants, children, and adolescents. The book offers an integrated approach to the science and clinical practice of pediatric hepatology and charts the substantial progress in understanding and treating these diseases. Chapters are written by international experts and address the unique pathophysiology, manifestations, and management of these disorders in the pediatric population. The third edition has been thoroughly updated and features new contributions on liver development, cholestatic and autoimmune disorders, fatty liver disease, and inborn errors of metabolism. With the continued evolution of pediatric hepatology as a discipline, this text remains an essential reference for all physicians involved in the care of children with liver disease.

Disease Control Priorities, Third Edition (Volume 6)
Disease Control Priorities, Third Edition (Volume 6)

Author: King K. Holmes

Publisher: World Bank Publications

Published: 2017-11-06

Total Pages: 1027

ISBN-13: 1464805253

DOWNLOAD EBOOK

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.